Literature DB >> 21357925

Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review.

D De Luca1, P Cogo, E Zecca, M Piastra, D Pietrini, A Tridente, G Conti, V P Carnielli.   

Abstract

Administration of drugs directly into the respiratory tree first was proposed a long time ago. Surfactant is the paradigmatic example of such therapies. Many other drugs have been used in the same way and further compounds are under investigation for this aim. In the last two decades, despite the wide number of drugs available for direct lung administration in critical care patients, few controlled data exist regarding their use in neonates and infants. This review will focus on drugs clinically available in a critical care setting for neonates and infants, including bronchodilators, pulmonary vasodilators, anti-inflammatory agents, mucolytics, resuscitative anti-infective agents, surfactants and other drugs. We provide an evidence-based comprehensive review of drugs available for intratracheal administration in paediatric and neonatal critical care and we examine possible advantages and risks for each proposed indication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357925     DOI: 10.1183/09031936.00024910

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Rescue hypothermia for refractory hypercapnia.

Authors:  Domenico Pietrini; Mariano Pennisi; Francesca Vitale; Silvia Maria Pulitanò; Giorgio Conti; Aldo Mancino; Marco Piastra; Daniele De Luca
Journal:  Eur J Pediatr       Date:  2012-06-13       Impact factor: 3.183

2.  The use of the Berlin definition for acute respiratory distress syndrome during infancy and early childhood: multicenter evaluation and expert consensus.

Authors:  Daniele De Luca; Marco Piastra; Giovanna Chidini; Pierre Tissieres; Edoardo Calderini; Sandrine Essouri; Alberto Medina Villanueva; Ana Vivanco Allende; Marti Pons-Odena; Luis Perez-Baena; Michael Hermon; Ascanio Tridente; Giorgio Conti; Massimo Antonelli; Martin Kneyber
Journal:  Intensive Care Med       Date:  2013-10-08       Impact factor: 17.440

3.  Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.

Authors:  Daniele De Luca; Ettore Capoluongo; Vincent Rigo
Journal:  BMC Pediatr       Date:  2011-11-08       Impact factor: 2.125

4.  Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.

Authors:  Daniele De Luca; Angelo Minucci; Marco Piastra; Paola E Cogo; Francesca Vendittelli; Laura Marzano; Leonarda Gentile; Bruno Giardina; Giorgio Conti; Ettore D Capoluongo
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

5.  PPARγ Signaling Mediates the Evolution, Development, Homeostasis, and Repair of the Lung.

Authors:  Virender K Rehan; John S Torday
Journal:  PPAR Res       Date:  2012-06-26       Impact factor: 4.964

6.  Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials.

Authors:  Beena G Sood; Martin Keszler; Meena Garg; Jonathan M Klein; Robin Ohls; Namasivayam Ambalavanan; C Michael Cotten; Monica Malian; Pablo J Sanchez; Satyan Lakshminrusimha; Leif D Nelin; Krisa P Van Meurs; Rebecca Bara; Shampa Saha; Abhik Das; Dennis Wallace; Rosemary D Higgins; Seetha Shankaran
Journal:  Trials       Date:  2014-12-12       Impact factor: 2.279

7.  Inhaled Pharmacotherapy for Neonates: A Narrative Review.

Authors:  Gustavo Rocha
Journal:  Turk Arch Pediatr       Date:  2022-01

Review 8.  Strategies to protect surfactant and enhance its activity.

Authors:  Daniele De Luca; Chiara Autilio
Journal:  Biomed J       Date:  2021-08-05       Impact factor: 4.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.